Tolerability of Grazax-R in Children

ALK-Abelló

Status and phase: Completed; Phase 1

Conditions: Allergy

Treatments: Biological: ALK Grass tablet

Study type: Interventional

Funder types: Industry

Identifiers

NCT00298701

GT-11

Details and patient eligibility

About

This trial is performed to assess whether the Grazax-R treatment is safe to use in children aged 5-12 years.

Sex: All

Ages: 5 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Grass pollen induced rhinoconjunctivitis
• Boys and girls, 5-12 years of age
• Positive skin prick test to grass pollen

Exclusion criteria

• Previous treatment with immunotherapy